We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. COMPASS Pathways plc (NASDAQ:CMPS) ...

Compass Pathways plc upgraded to Strong Buy after phase 3 COMP360 TRD data & fast-track FDA NDA review; see catalysts, ...

COMPASS Pathways stock has delivered a very strong 1 year return, yet its current valuation checks and market multiples point ...

Compass Pathways (CMPS) stock gains as Evercore ISI upgraded the company on the latest Phase 3 trial data for the company's ...

Shares of Compass Pathways climbed after the company said data from a late-stage trial of its drug for treatment-resistant depression confirmed its rapid onset and durable profile. The stock jumped 8.

As the psychedelic drug industry shifts from a speculative niche to a potential part of mainstream healthcare, investors have ...

Compass Pathways stock crumbled Tuesday despite seemingly positive test results for its psychedelic drug in treatment-resistant depression.

Compass has already submitted for approval of its psilocybin-based therapy to the FDA following previous Phase III success.

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against GRAIL, Inc. and certain of the Company's senior executives for securities fraud ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

ROYC, a leading global structuring and platform provider, today announced that Slättö, a Nordic private markets real estate firm, has selected ROYC to establish and manage a Luxembourg-domiciled ...